Swallow

Early modern Britain was terrified of women trying to swallow pins

Retrieved on: 
Tuesday, February 13, 2024

Though pin-swallowing is still sometimes identified in individual medical cases as having suicidal intent, this is often not the automatic conclusion.

Key Points: 
  • Though pin-swallowing is still sometimes identified in individual medical cases as having suicidal intent, this is often not the automatic conclusion.
  • But in early modern British society, where pins were ubiquitous, there were widespread fears about them being consumed.
  • The ready availability of pins meant that they were also a potential danger to those who wished to do themselves harm.
  • A young woman named Helen Fairfax was tempted to end her life using a pin at her family home in Yorkshire in 1621.
  • Early modern people believed that the devil was constantly looking for ways to tempt them towards sin.
  • The girl tried to swallow the items so often that they had “a box near full” of confiscated pins.

Hysterical women

  • It was increasingly associated with “hysteria”, an historical illness involving anxiety and excess emotion which was commonly associated with women, and the asylum.
  • By the 19th century, self-injurious behaviours such as swallowing or inserting pins into the body gained an increasingly moral dimension.
  • In his 1857 work, A Collection of Remarkable Cases in Surgery, the American surgeon Paul F. Eve (1806-1877) detailed a vast number of medical accounts.
  • This is despite the fact that the act of suicide was both a crime and a sin in this period.
  • Though early modern people were expected to resist the devil’s temptation, they were not necessarily held responsible for experiencing it.


Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Imogen Knox receives funding from the M4C/AHRC

Embrace the Fortune of Health this CNY with LAC's Activated Liver Protector and Belli Lean

Retrieved on: 
Thursday, February 8, 2024

As we embrace the moments of abundance, LAC's Activated Liver Protector and Belli Lean offer a helping hand to keep the delicate balance of health and celebration.

Key Points: 
  • As we embrace the moments of abundance, LAC's Activated Liver Protector and Belli Lean offer a helping hand to keep the delicate balance of health and celebration.
  • LAC Belli Lean works hand-in-hand with the body's natural metabolism, further enhancing the body to metabolise fat more effectively.
  • Crafted with natural ingredients, Belli Lean is a delicious and convenient way to reduce belly fat and look your best for gatherings with loved ones this year.
  • As the Chinese saying goes, "Health is Wealth" - our health remains paramount to our well-being even as we celebrate.

CWF Announces Canadian Conservation Achievement Awards

Retrieved on: 
Tuesday, June 20, 2023

OTTAWA, June 20, 2023 (GLOBE NEWSWIRE) -- The Canadian Wildlife Federation (CWF) is pleased to announce the recipients of the Canadian Conservation Achievement Awards.

Key Points: 
  • OTTAWA, June 20, 2023 (GLOBE NEWSWIRE) -- The Canadian Wildlife Federation (CWF) is pleased to announce the recipients of the Canadian Conservation Achievement Awards.
  • has dedicated nearly 20 years of her life to developing and delivering wildlife safety and conservation programs.
  • Applications for the Canadian Conservation Achievement Awards are accepted from November 1, 2023 to January 31, 2024.
  • “These awards highlight some of the outstanding achievements of conservation leaders across Canada,” said Rick Bates, CEO of CWF.

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

Retrieved on: 
Monday, April 3, 2023

FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced its support for Oral, Head & Neck Cancer Awareness Month in April and Oral, Head & Neck Cancer Awareness Week, April 16-22, both of which are organized by the Head & Neck Cancer Alliance (HCNA).

Key Points: 
  • FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced its support for Oral, Head & Neck Cancer Awareness Month in April and Oral, Head & Neck Cancer Awareness Week, April 16-22, both of which are organized by the Head & Neck Cancer Alliance (HCNA).
  • PDS Biotech recognizes the important role and dedication of patient organizations, such as the HCNA and the U.K.-based Swallows Head & Neck Cancer Support Group (The Swallows) in not only raising awareness of oral, head and neck cancer, but also in providing advice, information and education to those impacted by the disease.
  • PDS Biotech recently announced it is planning to initiate a randomized, controlled Phase 3 trial of the company’s lead clinical candidate, PDS0101, in combination with KEYTRUDA® (pembrolizumab) for the potential treatment of human papillomavirus (HPV)16-positive head and neck cancer.
  • We are proud to join these organizations during the month of April to celebrate the progress made while acknowledging that more is needed.

PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference

Retrieved on: 
Tuesday, October 25, 2022

PDS Biotech and The Swallows are both focused on improving the experience for patients impacted by head and neck cancer.

Key Points: 
  • PDS Biotech and The Swallows are both focused on improving the experience for patients impacted by head and neck cancer.
  • I am looking forward to an engaging discussion with researchers, current patients and survivors on how we can bring improved treatment options to these patients, said Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech.
  • The Swallows Head and Neck Cancer Group is a UK-based charity supporting all people affected by head and neck cancers: patients, caregivers, friends, or relatives.
  • Each November, we host an International Head & Neck Cancer Conference where we bring together those affected by head and neck cancer, health professionals and inspirational speakers.

Government of Canada and Birds Canada are stewarding bird conservation in Atlantic Canada

Retrieved on: 
Tuesday, June 7, 2022

That is why the Government of Canada is partnering with Birds Canada to steward local conservation projects to protect at-risk migratory birds and their habitats in Atlantic Canada.

Key Points: 
  • That is why the Government of Canada is partnering with Birds Canada to steward local conservation projects to protect at-risk migratory birds and their habitats in Atlantic Canada.
  • With the assistance of $384,594 from Environment and Climate Change Canada, Birds Canada has advanced three significant habitat projects in Atlantic Canada.
  • Birds Canada is a national non-profit, charitable organization dedicated to bird conservation.
  • Every day, thousands of caring donors, staff, and volunteers are taking action to increase the understanding, appreciation, and conservation of birds in Canada.

PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe

Retrieved on: 
Tuesday, May 31, 2022

PDS Biotech anticipates that enrollment in the UK could begin during the third quarter of 2022.

Key Points: 
  • PDS Biotech anticipates that enrollment in the UK could begin during the third quarter of 2022.
  • The acceptance of this CTA marks another important regulatory milestone for PDS Biotech.
  • Initiation of our global expansion is a key advancement to expedite enrollment into the VERSATILE-002 clinical study, stated Dr. Lauren Wood, Chief Medical Officer of PDS Biotech.
  • Additionally, this expansion allows PDS to expose global regulators to our novel molecularly targeted immunotherapies.

CPSC Marks the 60th Anniversary of National Poison Prevention Week and Dramatic Drop in Child Poisoning Deaths Over the Decades

Retrieved on: 
Monday, March 21, 2022

Recent increases in fatalities demonstrate the need for continued vigilance and work to limit and eventually eliminate these preventable tragedies."

Key Points: 
  • Recent increases in fatalities demonstrate the need for continued vigilance and work to limit and eventually eliminate these preventable tragedies."
  • National Poison Prevention Week began in 1962.
  • Since then, the poison prevention community, which includes the American Association of Poison Control Centers, standard development organizations, consumer advocates, medical professionals, industry and government have worked together to address pediatric poisoning.
  • Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually.

The iDentalwig™: New Dental Sensor™ System to Monitor the Body 24/7

Retrieved on: 
Tuesday, February 8, 2022

The iDentalWig is a wearable dental device that looks and feels a lot like our Dental Wig alternative to dental implants but stands out by having the ability to monitor the human body.

Key Points: 
  • The iDentalWig is a wearable dental device that looks and feels a lot like our Dental Wig alternative to dental implants but stands out by having the ability to monitor the human body.
  • Of course, there are machines and technology that monitor the body.
  • In fact, we believe that we can do something better in the form of the iDentalWig to monitor body functionality.
  • This New Dental Sensor System to Monitor the Body breakthrough technology has multiple applications.

Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

Retrieved on: 
Tuesday, February 8, 2022

We are dedicated to progressing this trial and look forward to the new insights it will provide, commented Dr. Lise Lund Kjems.

Key Points: 
  • We are dedicated to progressing this trial and look forward to the new insights it will provide, commented Dr. Lise Lund Kjems.
  • The Phase 3 study intends to enroll at least 93 pediatric (age 3 years and older) and adult patients with NPC1 in at least 23 study centers in 9 countries.
  • Eligible patients will be randomized 2:1 to receive either Trappsol Cyclo or a placebo.
  • For more information about the Companys TransportNPC pivotal Phase 3 study, visit www.ClinicalTrials.gov and reference identifier NCT04860960 .